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Introduction

•

•

• The most common type with about 85 percent of MS falling in this category
(Sammarco, Logan, Remington, 2018).
• Characterized by periods of worsening neurological symptoms followed by recovery
and remission (Sammarco, Logan, Remington, 2018).
Primary Progressive Multiple Sclerosis (PPMS)

Progressive Relapsing Multiple Sclerosis (PRMS)

TH1 cells are activated by an antigen in the periphery where they proliferate
and release cytokines and metalloproteinases that let the T cells cross the
blood brain barrier into the CNS (Sammarco, Logan, Remington, 2018).

•

The T cells (TH2) in the CNS are presented with myelin proteins that resemble
the antigen in the periphery. This reactivates the T- cells and along with B cells,
CD8+ T cells, and macrophages starts an inflammatory response that ends in
the destruction of the myelin sheath (Sammarco, Logan, Remington, 2018).

•

This inflammation causes demyelination of the CNS neuronal axons and leads to
axonal damage that causes neurological decline (Sammarco, Logan, Remington,
2018).

•

The myelin heals after an exacerbation, but is eventually replaced by a fibrotic
scar tissue (sclerosis). These are the white plaques commonly seen on MRI
(Capriotti, Noel, & Brissenden, 2018).

• Continual neurological deterioration with episodes of worsening (Capriotti, Noel, &
Brissenden, 2018).
Secondary Progressive Multiple Sclerosis ( SPMS)
• Most RRMS transition to this continually progressive form (Capriotti, Noel, &
Brissenden, 2018).

Disease Process

•

It affects around one million
people in the U.S. and up to 2.5
million in the world (Maloni,
2018).

•

There are several risk factors that seem to contribute to activation of the
autoimmune response (Sammarco, Logan, Remington, 2018). These risk factors
include genetic predisposition, heavy metal exposure, viral infections, and even
higher latitudes (Capriotti, Noel, & Brissenden, 2018).

•

It affects women more than
twice as much as men (Tur
&Thompson, 2015).

•

MS varies throughout the course of the disease. It usually starts with periods of
neurological impairment followed by remission. As it progresses, it can become
continuously and irreversibly debilitating (Capriotti, Noel, & Brissenden, 2018).

•

The median age of onset is
around 29 years old
(Wingerchuk & Carter, 2014).

•

The various disease courses can be seen in table 1.

•

Cost associated with MS are
more than 50,000 dollars per
year per person (Saguil, Kane,
& Farnell, 2014).

•
•

•

•

•

Magnetic Resonance Imaging (MRI) is the gold standard for diagnostic imaging with
evidence of possible MS (Saguil, Kane, & Farnell, 2014).

•

These diagnostic guidelines are based on the McDonald MS diagnostic criteria. The
revised version also includes new criteria that includes new sophisticated MRI
testing to help speed up diagnosis (Sammarco, Logan, Remington, 2018).
Other helpful diagnostic and treatment tests include evoked potential testing to
measure response of specific sensory pathways to stimulus and cerebrospinal fluid
analysis for specific immune system proteins (Capriotti, Noel, & Brissenden, 2018).

•

Prompt diagnosis and start of
treatment is ideal in managing
exacerbations and delaying the
progression of MS. The goal is to get
to diagnosis within 5 years (Saguil,
Kane, & Farnell, 2014).

•

The process is thought to be autoimmune
with the body turning on itself and
destroying the myelin sheaths of the CNS
nerves. So the main goal of treatment is
to stop this from taking place.

•

Majority of those with MS have RRMS,
and up to 85% will have an exacerbation
of severe symptoms (Saguil, Kane, &
Farnell, 2014).

•

It is important to rule out any other
possible conditions because there
are many that may mimic MS
(Sammarco, Logan, Remington, 2018).

•

With these exacerbations, the
inflammation is actively injuring the
myelin sheath as well as the axon. The
most effective way to treat this is to help
deescalate the inflammatory process
with corticosteroids. When this is not
enough, plasma transfers might be
needed (Saguil, Kane, & Farnell, 2014).

•

Once there is a diagnosis of MS, it is
important to start DMTs. The DMTs
should be monitored by a specialist,
usually a neurologist (Capriotti,
Noel, & Brissenden, 2018).

•

DMTs help to slow the progression
and decrease the disease activity of
MS, but symptom management is
also needed so the individual can
optimally live their lives (Sammarco,
Logan, Remington, 2018).

•

Educating the individual and the
family about the MS diagnosis,
treatments, and available resources
is very important. It will help them
understand the disease and what
they could expect in the future.

Since MS is considered an autoimmune
disease, treatment involves
immunomodulators, specifically disease
modifying therapies (DMT) (Capriotti,
Noel, & Brissenden, 2018).

Signs and Symptoms
•

The first suspected clinical presentation of possible MS is called clinically isolated
syndrome (CIS) and is not enough for diagnosis of MS (Sammarco, Logan,
Remington, 2018).

The neurologic deficits must be in two separate parts of the CNS, last longer than 24
hours, and happened at least one month apart. All other etiologies must also be
ruled out (Sammarco, Logan, Remington, 2018).

Due to the progressive, debilitating
nature of MS. It takes a
multidisciplinary approach to
successfully care for an individual
with MS (Sammarco, Logan,
Remington, 2018).

Knowing the pathophysiology of MS
helps one understand the process in
which the damage is being done to
create the clinical signs and symptoms of
MS.

•

There is no single test or clinical presentation that is specifically diagnostic of MS
(Capriotti, Noel, & Brissenden, 2018).

Diagnosis of MS must include “two neurologic deficits separated in time and space,
in the absence of fever, infection, or competing etiologies” (Saguil, Kane, & Farnell,
2014).

Implications for Care
•

•

Diagnosis

•
(National Multiple Sclerosis Society, 2018)

•

• Continuous worsening without remission after onset (Sammarco, Logan, Remington,
2018).

It is one of the most common
causes of long-term disability
for young adults in the United
States (Capriotti, Noel, &
Brissenden, 2018).

MS has been very visible to me for
as long as I could remember. As a
child I remember asking my parents
why a young individual with MS was
in a wheelchair. In high school and
college, I ran races and raised money
for MS research. The last eight years
I have worked primarily as a
neurological nurse and have seen
and taken care of many MS patients.
The strength and courage of
individuals with MS is what
motivated me to learn more about
the disease and share it with others.

Although the cause of MS is unknown, it thought to be a immune- mediated
disease. Individuals that are susceptible to MS through various risk factors,
including genetic predisposition, are exposed to an antigen that starts a
immune response that causes inflammation and ultimately destruction of the
myelin sheath that cover neuronal axons (Sammarco, Logan, Remington, 2018).

Remitting Relapsing Multiple Sclerosis (RRMS)

Multiple Sclerosis (MS) is a chronic
and progressive central nervous
system (CNS) disease with a largely
unknown etiology. It is a
autoimmune demyelinating disorder
that causes inflammation and
scarring on the myelin sheaths of
neuronal axons. Because it affects
the CNS, it has many debilitating
signs and symptoms that involve the
sensory, motor, cognitive, and
autonomic systems (Capriotti, Noel,
& Brissenden, 2018).

Significance of
Pathophysiology

Pathophysiology

Table 1. Disease Courses of Multiple Sclerosis

(Taylor, 2018)
Table 2.

Signs
•
•
•
•
•
•

Visual deficits (unilateral at
onset)
Ataxia
Spasticity
Decreased sensation
Muscle weakness, decreased
strength
Nystagmus

*ALL SIGNS AND SYMPTOMS
RELATED TO CNS IMPAIRMENT
(Saguil, Kane, & Farnell, 2014).

Symptoms
•
•
•
•
•
•
•
•
•
•
•

Fatigue
Sensory Impairment including
numbness and paresthesia (early
complaint)
Gait disturbances/Incoordination
Weakness
Visual disturbances
Heat sensitivity
Pain
Depression (more common) or
Euphoria
Dizziness
Hearing loss or tinnitus
Urinary symptoms

•

First symptoms are commonly unilateral
optic, motor, or sensory deficits. These
include optic neuritis, weakness, balance
problems, and numbness/tingling
(Capriotti, Noel, & Brissenden, 2018).
The optic and cerebellar nerves are
heavily myelinated and thus are the first
to be attacked (Capriotti, Noel, &
Brissenden, 2018).

•

A unique sign of MS is the Lhermitte sign
which is a jolt-like sensation that moves
down the spine with the flexion of the
neck (Saguil, Kane, & Farnell, 2014).

•

Uhthoff sign is also unique to MS and is
the worsening of symptoms when the
body experiences a rise in core body
temperature (Saguil, Kane, & Farnell,
2014).

•

A full list of signs and symptoms can be
seen in Table 2.

Conclusions
•

Multiple Sclerosis is a debilitating
disease of the CNS that affects
people in the prime of their lives.

•

Accurate diagnosis and treatment
followed by great interdisciplinary
care is needed for a person with MS.
Not only to slow the progression of
the disease, but to help prevent
disability and treat symptoms so
that they can live a more fulfilled
life.

•

There is need for more research not
only for more effective treatments,
but for what causes MS. Without
knowing what the cause is, it limits
the possible treatment options
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